Matt bought into a business model with shareholder money. He didn't invent anything. The premium it cost us to buy into the stem cell biz is what we deal with today. Have we captialized on bought stem cells? Can big Pharma do the same thing with less risk to shareholders? It looks like most stem cell stocks are doing poorly. If this stock is the next rocket, I can wait until Matt figures out how to lite the fuse.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.